1
|
Brubacher JR, Chan H, Erdelyi S, Yuan Y, Daoust R, Vaillancourt C, Rowe B, Lee J, Mercier E, Atkinson P, Davis P, Clarke D, Taylor J, Macpherson A, Emond M, Al-Hakim D, Horwood C, Wishart I, Magee K, Rao J, Eppler J. High-'n'-dry? A comparison of cannabis and alcohol use in drivers presenting to hospital after a vehicular collision. Addiction 2023; 118:1507-1516. [PMID: 36898848 DOI: 10.1111/add.16186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Accepted: 02/20/2023] [Indexed: 03/12/2023]
Abstract
DESIGN This was a prospective observational study. BACKGROUND AND AIMS The characteristics of cannabis-involved motor vehicle collisions are poorly understood. This study of injured drivers identifies demographic and collision characteristics associated with high tetrahydrocannabinol (THC) concentrations. SETTING The study was conducted in 15 Canadian trauma centres between January 2018 and December 2021. CASES The cases (n = 6956) comprised injured drivers who required blood testing as part of routine trauma care. MEASUREMENTS We quantified whole blood THC and blood alcohol concentration (BAC) and recorded driver sex, age and postal code, time of crash, crash type and injury severity. We defined three driver groups: high THC (THC ≥ 5 ng/ml and BAC = 0), high alcohol (BAC ≥ 0.08% and THC = 0) and THC/BAC-negative (THC = 0 = BAC). We used logistic regression techniques to identify factors associated with group membership. FINDINGS Most injured drivers (70.2%) were THC/BAC-negative; 1274 (18.3%) had THC > 0, including 186 (2.7%) in the high THC group; 1161 (16.7%) had BAC > 0, including 606 (8.7%) in the high BAC group. Males and drivers aged less than 45 years had higher adjusted odds of being in the high THC group (versus the THC/BAC-negative group). Importantly, 4.6% of drivers aged less than 19 years had THC ≥ 5 ng/ml, and drivers aged less than 19 years had higher unadjusted odds of being in the high THC group than drivers aged 45-54 years. Males, drivers aged 19-44 years, rural drivers, seriously injured drivers and drivers injured in single-vehicle, night-time or weekend collisions had higher adjusted odds ratios (aORs) for being in the high alcohol group (versus THC/BAC-negative). Drivers aged less than 35 or more than 65 years and drivers involved in multi-vehicle, daytime or weekday collisions had higher adjusted odds for being in the high THC group (versus the high BAC group). CONCLUSIONS In Canada, risk factors for cannabis-related motor vehicle collisions appear to differ from those for alcohol-related motor vehicle collisions. The collision factors associated with alcohol (single-vehicle, night-time, weekend, rural, serious injury) are not associated with cannabis-related collisions. Demographic factors (young drivers, male drivers) are associated with both alcohol and cannabis-related collisions, but are more strongly associated with cannabis-related collisions.
Collapse
Affiliation(s)
- J R Brubacher
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - H Chan
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - S Erdelyi
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - Y Yuan
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - R Daoust
- Department of Emergency Medicine, University of Montréal, Montréal, QC, Canada
| | - C Vaillancourt
- Department of Emergency Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | - B Rowe
- Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada
| | - J Lee
- Department of Emergency Medicine, University of Toronto, Toronto, ON, Canada
| | - E Mercier
- Department of Emergency Medicine, Université Laval, Québec City, QC, Canada
| | - P Atkinson
- Department of Emergency Medicine, Dalhousie Medicine New Brunswick, St John, NB, Canada
| | - P Davis
- Department of Emergency Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | - D Clarke
- Department of Surgery (Neurosurgery), Dalhousie University, Halifax, NS, Canada
| | - J Taylor
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - A Macpherson
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - M Emond
- Department of Emergency Medicine, Université Laval, Québec City, QC, Canada
| | - D Al-Hakim
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| | - C Horwood
- Department of Emergency Medicine, Memorial University, St John, NB, Canada
| | - I Wishart
- Department of Emergency Medicine, University of Calgary, Calgary, AB, Canada
| | - K Magee
- Department of Emergency Medicine, Dalhousie University, Halifax, NS, Canada
| | - J Rao
- Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada
| | - J Eppler
- Department of Emergency Medicine, University of British Columbia, Columbia, BC, Canada
| |
Collapse
|
2
|
Chan S, Pittayanon R, Wang HP, Chen JH, Teoh AY, Kuo YT, Tang RS, Yip HC, Ng SKK, Wong S, Mak JWY, Chan H, Lau L, Lui RN, Wong M, Rerknimitr R, Ng EK, Chiu PWY. Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial. Gut 2023; 72:638-643. [PMID: 36307177 PMCID: PMC10086285 DOI: 10.1136/gutjnl-2022-327007] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 09/28/2022] [Indexed: 12/08/2022]
Abstract
INTRODUCTION Over-the-scope clip (OTSC) has been used recently for primary haemostasis of peptic ulcers. This study aimed to compare the efficacy of OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of size ≥1.5 cm. The target population accounts for only 2.5% of all upper GI bleeders. METHODS This was a multicentre international randomised controlled trial from July 2017 to October 2020. All patients with Forest IIa or above peptic ulcers of ≥1.5 cm were included. Primary outcome was 30-day clinical rebleeding. Secondary endpoints include 3-day all-cause mortality, transfusion requirement, hospital stay, technical and clinical success, and further interventions. 100 patients are needed to yield a power of 80% to detect a difference of -0.15 at the 0.05 significance level (alpha) using a two-sided Z-test (pooled). RESULTS 100 patients were recruited. Success in achieving primary haemostasis was achieved in 46/50 (92%) and 48/50 (96%) in the OTSC and conventional arm, respectively. Among patients who had success in primary haemostasis, 2/46 (4.35%) patients in the OTSC arm and 9/48 (18.75%) patients in the conventional arm developed 30-day rebleeding (p=0.03). However, in an intention-to-treat analysis, there was no difference in rebleeding within 30 days (5/50 (10%) OTSC vs 9/50 (18%) standard, p=0.23) or all-cause mortality (2/50 (4%) OTSC vs 4/50 (8%) standard, p=0.68; OR=2.09, 95% CI 0.37 to 11.95). There was also no difference in transfusion requirement, hospital stay, intensive care unit admission and further interventions. CONCLUSION The routine use of OTSC as primary haemostasis in large bleeding peptic ulcers was not associated with a significant decrease in 30-day rebleeding. TRIAL REGISTRATION NUMBER NCT03160911.
Collapse
Affiliation(s)
- Shannon Chan
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Rapat Pittayanon
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Hsiu-Po Wang
- Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - Jiann-Hwa Chen
- Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei, Taiwan
| | - Anthony Yb Teoh
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Yu Ting Kuo
- Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - Raymond Sy Tang
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Hon Chi Yip
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Stephen Ka Kei Ng
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Sunny Wong
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Joyce Wing Yan Mak
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Heyson Chan
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Louis Lau
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Rashid N Lui
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Marc Wong
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Rungsun Rerknimitr
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Enders K Ng
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Philip Wai Yan Chiu
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
3
|
Mitra J, Bhushan C, Ghose S, Mills D, Chan H, Tarasek M, Foo T, Wells S, Jupitz S, Bednarz B, Brace C, Holmes J, Yeo D. Abstract No. 49 Motion Compensation in 3D MRI-US Fusion Using Fast Deformable Registration: A Feasibility Study for Real-Time Intervention. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
4
|
Mathieu A, Chan H, Coste V, Dutheil C. Scleritis and choroidal granuloma in a young patient with sarcoidosis. J Fr Ophtalmol 2022; 45:e446-e449. [DOI: 10.1016/j.jfo.2022.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/29/2022] [Accepted: 03/31/2022] [Indexed: 11/26/2022]
|
5
|
Lau JYW, Pittayanon R, Kwek A, Tang RS, Chan H, Rerknimitr R, Lee J, Ang TL, Suen BY, Yu YY, Chan FKL, Sung JJY. Comparison of a Hemostatic Powder and Standard Treatment in the Control of Active Bleeding From Upper Nonvariceal Lesions : A Multicenter, Noninferiority, Randomized Trial. Ann Intern Med 2022; 175:171-178. [PMID: 34871051 DOI: 10.7326/m21-0975] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The effectiveness of the hemostatic powder TC-325 as a single endoscopic treatment for acute nonvariceal upper gastrointestinal bleeding is uncertain. OBJECTIVE To compare TC-325 with standard endoscopic hemostatic treatments in the control of active bleeding from nonvariceal upper gastrointestinal causes. DESIGN One-sided, noninferiority, randomized, controlled trial. (ClinicalTrials.gov: NCT02534571). SETTING University teaching hospitals in the Asia-Pacific region. PATIENTS 224 adult patients with acute bleeding from a nonvariceal cause on upper gastrointestinal endoscopy. INTERVENTION TC-325 (n = 111) or standard hemostatic treatment (n = 113). MEASUREMENTS The primary outcome was control of bleeding within 30 days. Other outcomes included failure to control bleeding during index endoscopy, recurrent bleeding after initial hemostasis, further interventions, blood transfusion, hospitalization, and death. RESULTS 224 patients were enrolled (136 with gastroduodenal ulcers [60.7%], 33 with tumors [14.7%], and 55 with other causes of bleeding [24.6%]). Bleeding was controlled within 30 days in 100 of 111 patients (90.1%) in the TC-325 group and 92 of 113 (81.4%) in the standard treatment group (risk difference, 8.7 percentage points [1-sided 95% CI, 0.95 percentage point]). There were fewer failures of hemostasis during index endoscopy with TC-325 (3 [2.7%] vs. 11 [9.7%]; odds ratio, 0.26 [CI, 0.07 to 0.95]). Recurrent bleeding within 30 days did not differ between groups (9 [8.1%] vs. 10 [8.8%]). The need for further interventions also did not differ between groups (further endoscopic treatment: 8 [7.2%] vs. 10 [8.8%]; angiography: 2 [1.8%] vs. 4 [3.5%]; surgery: 1 [0.9%] vs. 0). There were 14 deaths in each group (12.6% vs. 12.4%). LIMITATION Clinicians were not blinded to treatment. CONCLUSION TC-325 is not inferior to standard treatment in the endoscopic control of bleeding from nonvariceal upper gastrointestinal causes. PRIMARY FUNDING SOURCE General Research Fund to the University Grants Committee, Hong Kong SAR Government.
Collapse
Affiliation(s)
- James Y W Lau
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (J.Y.L., R.S.T., H.C., B.S., F.K.C.)
| | - Rapat Pittayanon
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand (R.P., R.R.)
| | - Andrew Kwek
- Changi General Hospital, Singapore (A.K., J.L., T.L.A.)
| | - Raymond S Tang
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (J.Y.L., R.S.T., H.C., B.S., F.K.C.)
| | - Heyson Chan
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (J.Y.L., R.S.T., H.C., B.S., F.K.C.)
| | - Rungsun Rerknimitr
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand (R.P., R.R.)
| | - June Lee
- Changi General Hospital, Singapore (A.K., J.L., T.L.A.)
| | | | - Bing-Yee Suen
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (J.Y.L., R.S.T., H.C., B.S., F.K.C.)
| | - Yuan-Yuan Yu
- Department of Surgery, Prince of Wales Hospital, Shatin, Hong Kong (Y.Y.)
| | - Francis K L Chan
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (J.Y.L., R.S.T., H.C., B.S., F.K.C.)
| | | |
Collapse
|
6
|
Chan H, Dennis M, Coggins A. Cardiac Catheter Laboratory Utilisation Following Introduction of an Extracorporeal Membrane Oxygenation Cardiopulmonary Resuscitation (e-CPR) Programme for Out-of-Hospital Cardiac Arrest. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
7
|
Trotman J, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj‐Teague M, Zinzani PL, Coleman M, Browett P, Ke X, Sun M, Marcus R, Portell C, Thieblemont C, Zhou K, Liberati AM, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Kim JS, Talaulikar D, Co M, Zhou W, Huang J, Opat S. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.19_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Trotman
- Concord Repatriation General Hospital University of Sydney Oncology Concord Australia
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - K. Linton
- The Christie Hematology Manchester UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Oncology Glasgow UK
| | - B. Hu
- Levine Cancer Institute/Atrium Health Oncology Charlotte USA
| | - H. Chan
- North Shore Hospital Haematology Auckland New Zealand
| | - J. Jin
- The First Affiliated Hospital Zhejiang University Hematology Hangzhou China
| | | | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Hematology Bologna Italy
| | - M. Coleman
- Clinical Research Alliance Hematology Lake Success USA
| | - P. Browett
- Auckland City Hospital Haematology Grafton New Zealand
| | - X. Ke
- Peking University Third Hospital Hematology Beijing China
| | - M. Sun
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences Peking Union Medical College Hematology Tianjin China
| | - R. Marcus
- Sarah Cannon Research Institute UK Oncology London UK
| | - C. Portell
- University of Virginia Health System Hematology/Oncology Charlottesville USA
| | - C. Thieblemont
- APHP, Hôpital Saint‐Louis, Hemato‐oncology Paris University Diderot Hematology/Oncology Paris France
| | - K. Zhou
- Henan Cancer Hospital Oncology Zhengzhou China
| | - A. M. Liberati
- Azienda Ospedaliera Santa Maria Di Terni Oncology Terni Italy
| | - E. Bachy
- Centre Hospitalier Lyon Sud Pierre Bénite Hematology Rhone Italy
| | - F. Cavallo
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Hematology Torino Italy
| | - Rég. Costello
- Hôpital de la Conception – APHM Hematology Marseille France
| | - S. Iyengar
- Royal Marsden Hospital Haematology London UK
| | - R. Marasca
- AOU Policlinico di Modena Hematology Modena Italy
| | - H. Mociková
- Fakultní nemocnice Královské Vinohrady Hematology Praha 10 Czech Republic
| | - J. S. Kim
- Severance Hospital Hematology Seoul Korea
| | - D. Talaulikar
- The Canberra Hospital Haematology Canberra Australia
| | - M. Co
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - W. Zhou
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - J. Huang
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - S. Opat
- Monash Health Monash University Haematology Clayton Australia
| |
Collapse
|
8
|
Jomaa E, Chan H, Bentata R, Lapeyre G, Dutheil C. Idiopathic choroidal neovascularization in a young boy. J Fr Ophtalmol 2021; 44:1102-1104. [PMID: 33966915 DOI: 10.1016/j.jfo.2020.11.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Revised: 11/21/2020] [Accepted: 11/23/2020] [Indexed: 11/25/2022]
Affiliation(s)
- E Jomaa
- Centre hospitalier de Périgueux, 80, avenue George-Pompidou, 24000 Périgueux, France; Centre hospitalier universitaire de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France.
| | - H Chan
- Centre hospitalier de Périgueux, 80, avenue George-Pompidou, 24000 Périgueux, France
| | - R Bentata
- Centre hospitalier de Périgueux, 80, avenue George-Pompidou, 24000 Périgueux, France
| | - G Lapeyre
- Centre hospitalier universitaire de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Dutheil
- Centre hospitalier de Périgueux, 80, avenue George-Pompidou, 24000 Périgueux, France; Centre hospitalier universitaire de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| |
Collapse
|
9
|
Gualtieri T, Ferrari M, Taboni S, Chan H, Townson J, Mattavelli D, Sahovaler A, Eu D, Dey K, Mathews S, Re F, Bernardi S, Borsani E, Viswanathan S, Nicolai P, Sartore L, Russo D, Gilbert R, Irish J. 3D-mapping of mesenchymal stem cells growth on bioengineered scaffolds for maxillofacial skeleton regeneration: a preclinical, in vitro study. Cytotherapy 2021. [DOI: 10.1016/s146532492100517x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Andres T, Lapeyre G, Chan H, Saunier V, Coste V, Touboul D. [Cogan's syndrome]. J Fr Ophtalmol 2021; 44:e419-e421. [PMID: 33902936 DOI: 10.1016/j.jfo.2020.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 11/05/2020] [Indexed: 11/26/2022]
Affiliation(s)
- T Andres
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France.
| | - G Lapeyre
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - H Chan
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - V Saunier
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - V Coste
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - D Touboul
- Groupe hospitalier Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| |
Collapse
|
11
|
Koudsie S, Coste-Verdier V, Paya C, Chan H, Andrebe C, Pechmeja J, Leoni S, Korobelnik JF. [Long term outcomes of botulinum toxin injections in infantile esotropia]. J Fr Ophtalmol 2021; 44:509-518. [PMID: 33632627 DOI: 10.1016/j.jfo.2020.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 06/19/2020] [Accepted: 07/02/2020] [Indexed: 11/26/2022]
Abstract
PURPOSE To evaluate long terms outcomes of botulinum toxin in infantile esotropia by measuring the amount of microtropia 24 months after injection. Secondary purpose was to identify predictive factors of microtropia. METHODS A retrospective, single-center study was performed at the university medical center in Bordeaux between 2001 and 2018, including all patients with infantile esotropia greater than 20 D. All patients received 5 or 7,5 IU of botulinum toxin A in each medial rectus, once or twice depending on the angle of deviation after the first injection and after wearing full optical correction at least two months. We noted the angle at 1, 6, 12 and 24 months, the occurrence of any complications and the need for later strabismus surgery. The primary endpoint was the achievement of a microtropia less than 8 diopters (D) at 24 months post-injection. We evaluated the predictive factors for microtropia with a Fischer's test. RESULTS We included 30 patients with esotropia greater than 20 D. The mean follow-up after injection was 48 months ±30. The mean age was 16.24 months (7-29 months) with a female predominance in the population (SR=0.43). The mean pre-injection deviation was 41.25±12.17 D. The majority of patients were mildly (40%) or moderately (40%) hyperopic. At 24 months, 46.7% microtropias were obtained (95% CI: 28.9%-64.5%). The change in mean angle at 1, 6, 12 and 24 months post-injection was -8.57±25.21 D; 14.48±13.40 D; 18.38±12.07 D and 21.23±14.97 D, respectively. No factors were predictive of microtropia. Of the 30 children, 3 had transient ptosis requiring strips and 12 showed an exotropia at 1 month. All complications were self-limited and without consequences. 3 children had a second injection of botulinum toxin, which in 2/3 of the cases resulted in a long-lasting microtropia. 26.7% (n=8) of the children underwent secondary surgery. Obtaining a microtropia 24 months after injection statistically significantly reduced the need for secondary strabismus surgery: 92.9% P=0.039% CI 95% (0.002; 1.0606). CONCLUSION Botulinum toxin appears to be a less invasive and more conservative alternative to surgery in children with infantile esotropia. In 46.7% of cases, microtropia is achieved. An improvement was noted in 90% (n=27) of the children with a reduction of half (21.23 D) of the mean post-injection angle at 24 months. When effective, it significantly reduces the need for secondary surgery.
Collapse
Affiliation(s)
- S Koudsie
- Service ophtalmologie, centre Francois Xavier Michelet, CHU de Bordeaux, Bordeaux, France.
| | - V Coste-Verdier
- Service ophtalmologie, centre Francois Xavier Michelet, CHU de Bordeaux, Bordeaux, France
| | - C Paya
- Ophtalmologie Palais Gallien, Bordeaux, France
| | - H Chan
- Service ophtalmologie, centre Francois Xavier Michelet, CHU de Bordeaux, Bordeaux, France
| | - C Andrebe
- Service ophtalmologie, centre Francois Xavier Michelet, CHU de Bordeaux, Bordeaux, France
| | - J Pechmeja
- Service ophtalmologie, CHR Purpan, Toulouse, France
| | - S Leoni
- Centre ophtalmologique Hélios, Saint-Jean-de-Luz, France
| | - J-F Korobelnik
- Service ophtalmologie, centre Francois Xavier Michelet, CHU de Bordeaux, Bordeaux, France
| |
Collapse
|
12
|
Chan H, Ribeiro RV, Haden S, Hirani V. Plant-Based Dietary Patterns, Body Composition, Muscle Strength and Function in Middle and Older Age: A Systematic Review. J Nutr Health Aging 2021; 25:1012-1022. [PMID: 34545922 DOI: 10.1007/s12603-021-1666-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Sarcopenia is prevalent in middle-aged and older adults. A plant-based diet may be linked to changes in body composition and musculoskeletal health. OBJECTIVE This systematic review aimed to investigate the effects of plant-based dietary patterns on the body composition, muscle strength and function in middle-aged and older adults. PRISMA guidelines were followed. METHOD A systematic search was completed on databases including MEDLINE, Embase, Global Health, PREMEDLINE, Cochrane library, CINAHL and Scopus on articles published until 1st March 2019. Search terms included 'middle-aged', 'older adult', 'plant-based diet' and 'muscle strength'. Title and abstract screening were conducted on 1,868 publications after deduplication. Sample size, subject characteristics, recruitment, inclusion and exclusion criteria, dietary measures, health outcome measures, statistical results and confounders were sorted by author, study type, year and country. The quality of evidence of extracted data was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tools. RESULTS/CONCLUSIONS 17 papers were included from 31 articles selected for full review. The majority of the studies were cross-sectional studies (n = 9) and RCTs (n = 6).The remaining studies were cohort studies. Positive associations were found between plant-based dietary patterns; negative association with body composition; and inconclusive association with muscle function. However, further studies are needed to improve the understanding.
Collapse
Affiliation(s)
- H Chan
- Hilaria Hin Lam Chan, The University of Sydney, Australia,
| | | | | | | |
Collapse
|
13
|
Zhang X, Yang F, Chen R, Tsang L, Jiang X, Chan H. Dedifferentiation-reprogrammed human mesenchymal stem cells for treating ischaemic stroke: abridged secondary publication. Hong Kong Med J 2020; 26 Suppl 8:41-45. [PMID: 33504678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Open
Affiliation(s)
- X Zhang
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
- Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu
| | - F Yang
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
| | - R Chen
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
| | - L Tsang
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
| | - X Jiang
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
- The Chinese University of Hong Kong, Shenzhen Research Institute, Shenzhen
| | - H Chan
- Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
- Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu
- The Chinese University of Hong Kong, Shenzhen Research Institute, Shenzhen
| |
Collapse
|
14
|
Bentata R, Chan H, Coste V, Delyfer MN, Ducassou S, Léger F, Korobelnik JF. [Pseudo-hypopyon secondary to a meningeal recurrence of acute lymphoblastic leukemia: Case report]. J Fr Ophtalmol 2020; 43:e259-e261. [PMID: 32800420 DOI: 10.1016/j.jfo.2020.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 12/22/2019] [Accepted: 01/03/2020] [Indexed: 11/18/2022]
Affiliation(s)
- R Bentata
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France.
| | - H Chan
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - V Coste
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - M-N Delyfer
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - S Ducassou
- Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France; Service d'onco-hématologie pédiatrique, CHU Pellegrin, Bordeaux, France
| | - F Léger
- Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France; Service d'anatomopathologie, CHU Pellegrin, Bordeaux, France
| | - J-F Korobelnik
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| |
Collapse
|
15
|
Chan H, Ooi G, Sridhar R, Low I, Lim S, Bagdasarian N. Measles in an Open Ward. J Infect Public Health 2020. [DOI: 10.1016/j.jiph.2020.01.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Drissi-Bakhkhat A, Guicheney M, Dutriaux C, Cirotteau P, Milpied B, Chan H, Dousset L, Duffau P, Seneschal J. Ophtalmoplégie isolée au cours d’un traitement par double immunothérapie pour un mélanome métastatique. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Daly MJ, Chan H, Muhanna N, Akens MK, Wilson BC, Irish JC, Jaffray DA. Intraoperative cone-beam CT spatial priors for diffuse optical fluorescence tomography. ACTA ACUST UNITED AC 2019; 64:215007. [DOI: 10.1088/1361-6560/ab4917] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
18
|
Bentata R, Chan H, Coste V, Delyfer MN, Chan G, Korobelnik JF. [Persistent pupillary membrane (Wachendorf membrane)]. J Fr Ophtalmol 2019; 42:808-810. [PMID: 31147100 DOI: 10.1016/j.jfo.2019.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2019] [Accepted: 03/13/2019] [Indexed: 11/18/2022]
Affiliation(s)
- R Bentata
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France.
| | - H Chan
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - V Coste
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - M-N Delyfer
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - G Chan
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - J-F Korobelnik
- Service d'ophtalmologie, CHU de Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| |
Collapse
|
19
|
Gomes B, Ribeiro R, Ramadan K, Galasso M, Ali A, Watanabe Y, Paradiso E, Meineri M, Chan H, Zhang Y, Hwang D, Slutsky A, Fan E, Liu M, Keshavjee S, Cypel M, del Sorbo L. Effect of PEEP-Induced Alveolar Recruitment on Lung Injury during Extracorporeal Membrane Oxygenation for ARDS. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
20
|
Thompson S, Chan H, Thorne L, Watkins L, Toma A. TM3-4 The effect of acetazolamide on intracranial pressure: primary study with prolonged continuous intracranial pressure monitoring. J Neurol Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.50] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesAcetazolamide has frequently been used as a first-line treatment for idiopathic Intracranial Hypertension (IIH) and other disorders which lead to a non-acute rise in intracranial pressure (ICP). The effect of acetazolamide has been observed through lumbar puncture, however the effect of acetazolamide on ICP has not been studied in continuous ICP measurement.DesignA retrospective study of a prospectively built ICP databaseSubjectsAll patients with continuous ICP monitoring demonstrating 24 hours on and 24 hours off acetazolamide were included in the study.MethodsPatients median ICP and median pulse amplitude over 24 hour monitoring period on and off Diamox was assessed.Results12 patients (9F, 3M) underwent ICP monitoring with data collected during the same admission. 8 patients had IIH, 1 Chiari Malformation, 3 new diagnostic ICP procedures. 10 patients saw a reduction in ICP while on acetazolamide. Overall, patients experienced a Median reduction of 1.14 mmHg (Mean 1.16 mmHg, Range 4.24 to −4.445 mmHg). Patients (n9) who were on ≥1 g of acetazolamide per day experienced a median reduction in ICP of 1.595 mmHg (Mean 1.91 mmHg, Range 4.24–0.5 mmHg).ConclusionsOur data suggests acetazolamide can reduce ICP quickly following commencement, however this reduction was relatively small. The effect seems greater with a higher dose. Larger numbers of patients are required to gain a greater understanding into the significance of acetazolamide on ICP, particularly the affect at larger doses.
Collapse
|
21
|
Chan H, Cougnard-Grégoire A, Korobelnik JF, Delyfer MN, Touboul D, Coste V, Sarlangue J, Dutheil C, Paya C. Screening for retinopathy of prematurity by telemedicine in a tertiary level neonatal intensive care unit in France: Review of a six-year period. J Fr Ophtalmol 2018; 41:926-932. [PMID: 30442486 DOI: 10.1016/j.jfo.2018.02.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Revised: 02/17/2018] [Accepted: 02/28/2018] [Indexed: 10/27/2022]
Abstract
PURPOSE To analyze the prevalence and risk factors for retinopathy of prematurity (ROP) and severe (treatment-requiring) ROP. METHODS A retrospective study was conducted in a level III neonatal unit in Bordeaux, France, from 2009 to 2015. Four hundred and nineteen preterm infants who were screened for ROP exclusively by RetCam were included. RESULTS ROP of any degree was diagnosed in 27.68% of infants. Stages 1, 2, 3 and 4 ROP was found in 44%, 46%, 9% and 1% of subjects, respectively. No stage 5 ROP was observed. 28/419 infants (6.6%) were treated exclusively with laser photocoagulation. No intravitreal anti-VEGF injections or surgical treatments were performed. No infants born at>31 weeks or with BW>1110g required ROP treatment. On multivariate analysis, risk factors for ROP development were low birth weight, low gestational age at birth, high duration of invasive mechanical ventilation, shock or use of vasopressors. On multivariate analysis, risk factors for severe, treatment-requiring ROP were male gender, gestational age≤27 weeks and Apgar score at 5minutes≤7. CONCLUSION In our 6-year series, ROP was successfully identified on screening exclusively by telemedicine, and no surgical treatment was required. This study identifies known ROP risk factors, but the Apgar score at 5minutes as a risk factor for severe ROP requires further studies in order to be confirmed.
Collapse
Affiliation(s)
- H Chan
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France.
| | - A Cougnard-Grégoire
- Inserm (institut national de la santé et de la recherche médicale), U897-épidemiologie-biostatistique, Bordeaux, France
| | - J F Korobelnik
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France; Inserm (institut national de la santé et de la recherche médicale), U897-épidemiologie-biostatistique, Bordeaux, France
| | - M N Delyfer
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France; Inserm (institut national de la santé et de la recherche médicale), U897-épidemiologie-biostatistique, Bordeaux, France
| | - D Touboul
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - V Coste
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - J Sarlangue
- Service de néonatologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Dutheil
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - C Paya
- Service d'ophtalmologie, centre hospitalier universitaire (CHU de Bordeaux), place Amélie-Raba-Léon, 33000 Bordeaux, France.
| |
Collapse
|
22
|
Kinoshita T, Ujiie H, Chen J, Ding L, Chan H, Gregor A, Bernards N, Mcveigh P, Fujino K, Lee C, Motooka Y, Inage T, Valic M, Weersink R, Wilson B, Zheng G, Asamura H, Yasufuku K. P3.16-05 A Nanotechnology-Enabled Strategy for Image-Guided Transbronchial and Transpleural Photothermal Therapy of Peripheral Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Philp L, Chan H, Rouzbahman M, Chen J, Zheng G, Bernardini M. Use of porphysomes for accurate intraoperative detection of lymph node metastases in an endometrial cancer model. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Abstract
OBJECTIVES To report outcomes following biofeedback for functional problems associated with an ileoanal pouch. Incontinence and evacuatory disorders associated with the ileoanal pouch can be particularly problematic and difficult to treat using conventional therapies. Biofeedback therapy is a behavioural treatment that offers a non-surgical approach as an alternative or adjunct for patients. MATERIALS AND METHODS This was a retrospective single centre study. We reviewed the notes of all patients attending for biofeedback at our institution between January 2012 and October 2017 and identified all those that did so for ileoanal pouch related problems. We recorded patient reported subjective improvements following biofeedback. The validated International Consultation on Incontinence Questionnaire was used to assess improvement in incontinent symptoms and the evacuatory disorder questionnaire was used to assess improvement in evacuatory disorders. RESULTS Twenty-six patients with ileoanal pouch related problems underwent biofeedback. Based on patients' feedback at next clinical encounter following biofeedback, nine reported much improvement, 11 reported some improvement and six reported no improvement. In the group treated for incontinence, quality of life improved significantly from a median pre-treatment score of 80 to a post-treatment score of 41 (p = .01). Biofeedback reduced pain, bloating straining and laxative use in patients with evacuatory disorders. CONCLUSIONS Biofeedback may be associated with significant improvement in quality of life as well as possible improvements in symptoms related to both incontinence and evacuatory disorders. It is probably an underused service. Further larger prospective studies are required to properly assess the efficacy of biofeedback in ileoanal pouch related dysfunction.
Collapse
Affiliation(s)
- Jonathan P Segal
- a St Mark's Hospital , Harrow , UK.,b Department of Surgery and Cancer , Imperial College , London , UK
| | | | | | - Omar D Faiz
- a St Mark's Hospital , Harrow , UK.,b Department of Surgery and Cancer , Imperial College , London , UK
| | - Susan K Clark
- a St Mark's Hospital , Harrow , UK.,b Department of Surgery and Cancer , Imperial College , London , UK
| | - Ailsa L Hart
- a St Mark's Hospital , Harrow , UK.,b Department of Surgery and Cancer , Imperial College , London , UK
| |
Collapse
|
25
|
Chan H, Hsu A, Angle J. 3:54 PM Abstract No. 207 Identifying risk factors for rebleeding after embolization for rectus sheath hematoma. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
26
|
Daly A, Pinto A, Evans S, Almeida M, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund Hansen K, Ter Horst N, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs G, Kok I, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Och U, Robert M, Rocha J, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Skeath R, Stolen L, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White F, White L, Zweers H, MacDonald A. Dietary practices in propionic acidemia: A European survey. Mol Genet Metab Rep 2017; 13:83-89. [PMID: 29021961 PMCID: PMC5633157 DOI: 10.1016/j.ymgmr.2017.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 09/21/2017] [Indexed: 12/02/2022] Open
Abstract
Background The definitive dietary management of propionic acidaemia (PA) is unknown although natural protein restriction with adequate energy provision is of key importance. Aim To describe European dietary practices in the management of patients with PA prior to the publication of the European PA guidelines. Methods This was a cross-sectional survey consisting of 27 questions about the dietary practices in PA patients circulated to European IMD dietitians and health professionals in 2014. Results Information on protein restricted diets of 186 PA patients from 47 centres, representing 14 European countries was collected. Total protein intake [PA precursor-free L-amino acid supplements (PFAA) and natural protein] met WHO/FAO/UNU (2007) safe protein requirements for age in 36 centres (77%). PFAA were used to supplement natural protein intake in 81% (n = 38) of centres, providing a median of 44% (14–83%) of total protein requirement. Seventy-four per cent of patients were prescribed natural protein intakes below WHO/FAO/UNU (2007) safe levels in one or more of the following age groups: 0–6 m, 7–12 m, 1–10 y, 11–16 y and > 16 y. Sixty-three per cent (n = 117) of patients were tube fed (74% gastrostomy), but only 22% received nocturnal feeds. Conclusions There was high use of PFAA with intakes of natural protein commonly below WHO/FAO/UNU (2007) safe levels. Optimal dietary management can only be determined by longitudinal, multi-centre, prospective case controlled studies. The metabolic instability of PA and small patient cohorts in each centre ensure that this is a challenging undertaking.
Collapse
Affiliation(s)
- A. Daly
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - A. Pinto
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - S. Evans
- Birmingham Women's and Children's Hospital, Birmingham, UK
| | - M.F. Almeida
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal
- Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal
| | - M. Assoun
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - A. Belanger-Quintana
- Unidad de Enfermedades Metabolicas, Servicio de Pediatria, Hospital Ramon y Cajal Madrid, Spain
| | - S.M. Bernabei
- Children Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy
| | | | - D. Cassiman
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | | | - H. Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - J. Dalmau
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - F. de Boer
- University of Groningen, University Medical Center Groningen, Netherlands
| | - C. de Laet
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - A. de Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - A. Dianin
- Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Italy
| | - M. Dixon
- Great Ormond Street Hospital for Children NHS FoundationTrust, London, UK
| | - K. Dokoupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S. Dubois
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - F. Eyskens
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A. Faria
- Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - I. Fasan
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - E. Favre
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - F. Feillet
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | | | - G. Gallo
- Children Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy
| | | | - J. Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - K. Kaalund Hansen
- Charles Dent Metabolic Unit National Hospital for Neurology and Surgery, London, UK
| | | | - C. Jankowski
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I. Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - G.E. Kahrs
- Haukeland University Hospital, Bergen, Norway
| | - I.L. Kok
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - A. Kowalik
- Institute of Mother & Child, Warsaw, Poland
| | - C. Laguerre
- Centre de Compétence de L'Hôpital des Enfants de Toulouse, France
| | - S. Le Verge
- Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France
| | - R. Lilje
- Oslo University Hospital, Norway
| | - C. Maddalon
- University Children's Hospital Zurich, Switzerland
| | - D. Mayr
- Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria
| | - U. Meyer
- Clinic of Paediatric Kidney, Liver- and Metabolic Diseases, Medical School Hannover, Germany
| | - A. Micciche
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - U. Och
- University Children's Hospital, Munster, Germany
| | - M. Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - J.C. Rocha
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal
- Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal
- Centre for Health Technology and Services Research (CINTESIS), Portugal
| | | | - C. Rohde
- Hospital of Children's & Adolescents, University of Leipzig, Germany
| | - K. Ross
- Royal Aberdeen Children's Hospital, Scotland
| | - I. Saruggia
- Centre de Reference des Maladies Héréditaires du Métabolisme du Pr. B. Chabrol CHU Timone Enfant, Marseille, France
| | - A. Schlune
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany
| | | | - E. Sjoqvist
- Children's Hospital, University Hospital, Lund, Sweden
| | - R. Skeath
- Great Ormond Street Hospital for Children NHS FoundationTrust, London, UK
| | | | - A. Terry
- Alder Hey Children's Hospital NHS Foundation Trust Liverpool, UK
| | - C. Timmer
- Academisch Medisch Centrum, Amsterdam, Netherlands
| | - L. Tomlinson
- University Hospitals Birmingham NHS Foundation Trust, UK
| | - A. Tooke
- Nottingham University Hospitals, UK
| | | | - E. van Dam
- University of Groningen, University Medical Center Groningen, Netherlands
| | - T. van den Hurk
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | | | | | - M. van Rijn
- University of Groningen, University Medical Center Groningen, Netherlands
| | | | - C. Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | - I. Vitoria
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - D. Webster
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | - F.J. White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - L. White
- Sheffield Children's Hospital, UK
| | - H. Zweers
- Radboud University Medical Center Nijmegen, Netherlands
| | - A. MacDonald
- Birmingham Women's and Children's Hospital, Birmingham, UK
- Corresponding author at: Dietetic Department, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.Dietetic DepartmentBirmingham Children's HospitalSteelhouse LaneBirminghamB4 6NHUK
| |
Collapse
|
27
|
Chan H. TRIPARTITE COLLABORATION ON DEMENTIA CARE BETWEEN HOSPITAL, COMMUNITY, AND FAMILY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H. Chan
- University Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, Hong Kong,
- Sau Po Centre on Ageing, The University of Hong Kong, Hong Kong, Hong Kong, Hong Kong
- University Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, Hong Kong,
| |
Collapse
|
28
|
Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet 2017; 389:2375-2382. [PMID: 28410791 DOI: 10.1016/s0140-6736(17)30981-9] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 03/27/2017] [Accepted: 03/27/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor is superior to a non-selective NSAID plus proton-pump inhibitor for prevention of recurrent ulcer bleeding in concomitant users of aspirin with previous ulcer bleeding. METHODS For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin. After ulcer healing, an independent staff member randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal bleeding within 18 months. The primary endpoint and secondary safety endpoints were analysed in the modified intention-to-treat population. This study was registered with ClinicalTrials.gov, number NCT00153660. FINDINGS Between May 24, 2005, and Nov 28, 2012, we enrolled 514 patients, assigning 257 patients to each study group, all of whom were included in the intention-to-treat population. Recurrent upper gastrointestinal bleeding occurred in 14 patients in the celecoxib group (nine gastric ulcers and five duodenal ulcers) and 31 patients in the naproxen group (25 gastric ulcers, three duodenal ulcers, one gastric ulcer and duodenal ulcer, and two bleeding erosions). The cumulative incidence of recurrent bleeding in 18 months was 5·6% (95% CI 3·3-9·2) in the celecoxib group and 12·3% (8·8-17·1) in the naproxen group (p=0·008; crude hazard ratio 0·44, 95% CI 0·23-0·82; p=0·010). Excluding patients who reached study endpoints, 21 (8%) patients in the celecoxib group and 17 (7%) patients in the naproxen group had adverse events leading to discontinuation of treatment. No treatment-related deaths occurred during the study. INTERPRETATION In patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib plus proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent upper gastrointestinal bleeding. Naproxen should be avoided despite its perceived cardiovascular safety. FUNDING The Research Grant Council of Hong Kong.
Collapse
Affiliation(s)
- Francis K L Chan
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
| | - Jessica Y L Ching
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Yee Kit Tse
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Kelvin Lam
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Grace L H Wong
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Siew C Ng
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Vivian Lee
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Kim W L Au
- Department of Surgery, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Pui Kuan Cheong
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Bing Y Suen
- Department of Surgery, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Heyson Chan
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Ka Man Kee
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Angeline Lo
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Vincent W S Wong
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Justin C Y Wu
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Moe H Kyaw
- Department of Medicine & Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
| |
Collapse
|
29
|
Ka S, Lo G, Ai V, Au-Yeung P, Chan H. The First Positron Emission Tomography-Magnetic Resonance Imaging in Hong Kong: Preliminary Experience. Hong Kong J Radiol 2017. [DOI: 10.12809/hkjr1716828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
30
|
Pinto A, Daly A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, Chan H, Dalmau J, de Boer F, de Laet C, de Meyer A, Desloovere A, Dianin A, Dixon M, Dokoupil K, Dubois S, Eyskens F, Faria A, Fasan I, Favre E, Feillet F, Fekete A, Gallo G, Gingell C, Gribben J, Kaalund-Hansen K, Horst N, Jankowski C, Janssen-Regelink R, Jones I, Jouault C, Kahrs GE, Kok IL, Kowalik A, Laguerre C, Le Verge S, Lilje R, Maddalon C, Mayr D, Meyer U, Micciche A, Robert M, Rocha JC, Rogozinski H, Rohde C, Ross K, Saruggia I, Schlune A, Singleton K, Sjoqvist E, Stolen LH, Terry A, Timmer C, Tomlinson L, Tooke A, Vande Kerckhove K, van Dam E, van den Hurk T, van der Ploeg L, van Driessche M, van Rijn M, van Teeffelen-Heithoff A, van Wegberg A, Vasconcelos C, Vestergaard H, Vitoria I, Webster D, White FJ, White L, Zweers H, MacDonald A. Dietary practices in isovaleric acidemia: A European survey. Mol Genet Metab Rep 2017; 12:16-22. [PMID: 28275552 PMCID: PMC5328917 DOI: 10.1016/j.ymgmr.2017.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Accepted: 02/14/2017] [Indexed: 12/21/2022] Open
Abstract
Background In Europe, dietary management of isovaleric acidemia (IVA) may vary widely. There is limited collective information about dietetic management. Aim To describe European practice regarding the dietary management of IVA, prior to the availability of the E-IMD IVA guidelines (E-IMD 2014). Methods A cross-sectional questionnaire was sent to all European dietitians who were either members of the Society for the Study of Inborn Errors of Metabolism Dietitians Group (SSIEM-DG) or whom had responded to previous questionnaires on dietetic practice (n = 53). The questionnaire comprised 27 questions about the dietary management of IVA. Results Information on 140 patients with IVA from 39 centres was reported. 133 patients (38 centres) were given a protein restricted diet. Leucine-free amino acid supplements (LFAA) were routinely used to supplement protein intake in 58% of centres. The median total protein intake prescribed achieved the WHO/FAO/UNU [2007] safe levels of protein intake in all age groups. Centres that prescribed LFAA had lower natural protein intakes in most age groups except 1 to 10 y. In contrast, when centres were not using LFAA, the median natural protein intake met WHO/FAO/UNU [2007] safe levels of protein intake in all age groups. Enteral tube feeding was rarely prescribed. Conclusions This survey demonstrates wide differences in dietary practice in the management of IVA across European centres. It provides unique dietary data collectively representing European practices in IVA which can be used as a foundation to compare dietary management changes as a consequence of the first E-IMD IVA guidelines availability.
Collapse
Affiliation(s)
- A Pinto
- Birmingham Children's Hospital, Birmingham, UK
| | - A Daly
- Birmingham Children's Hospital, Birmingham, UK
| | - S Evans
- Birmingham Children's Hospital, Birmingham, UK
| | - M F Almeida
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal
| | - M Assoun
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - A Belanger-Quintana
- Unidad de Enfermedades Metabolicas, Servicio de Pediatria, Hospital Ramon y Cajal Madrid, Spain
| | - S Bernabei
- Children's Hospital Bambino Gesù, Division of Metabolism, Rome, Italy
| | | | - D Cassiman
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | | | - H Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - J Dalmau
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - F de Boer
- University of Groningen, University Medical Center Groningen, Netherlands
| | - C de Laet
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - A de Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - A Dianin
- Pediatric Department, University Hospital of Borgo Roma Verona, Italy
| | - M Dixon
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - K Dokoupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S Dubois
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - F Eyskens
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A Faria
- Hospital Pediatrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - I Fasan
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - E Favre
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - F Feillet
- Reference center for Inborn Errors of Metabolism, Department of Pediatrics, Children's University Hospital, Nancy, France
| | - A Fekete
- Metabolic Centre of Vienna, Austria
| | - G Gallo
- Children's Hospital Bambino Gesù, Division of Metabolism, Rome, Italy
| | | | - J Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - K Kaalund-Hansen
- Charles Dent Metabolic Unit National Hospital for Neurology and Surgery, London, UK
| | - N Horst
- Emma Children's Hospital, AMC Amsterdam, Netherlands
| | - C Jankowski
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | | | - G E Kahrs
- Haukeland University Hospital, Bergen, Norway
| | - I L Kok
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - A Kowalik
- Institute of Mother & Child, Warsaw, Poland
| | - C Laguerre
- Centre de Compétence de L'Hôpital des Enfants de Toulouse, France
| | - S Le Verge
- Centre de référence des maladies héréditaires du métabolisme, hôpital Necker enfants Malades, Paris
| | - R Lilje
- Oslo University Hospital, Norway
| | - C Maddalon
- University Children's Hospital Zurich, Switzerland
| | - D Mayr
- Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria
| | - U Meyer
- Clinic of Paediatric Kidney, Liver and Metabolic Diseases, Medical School Hannover, Germany
| | - A Micciche
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | - J C Rocha
- Centro de Genética Médica, Centro Hospitalar do Porto - CHP, Porto, Portugal; Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal; Centre for Health Technology and Services Research (CINTESIS), Portugal
| | - H Rogozinski
- Bradford Teaching Hospital NHS Foundation Trust, UK
| | - C Rohde
- Hospital of Children's & Adolescents, University of Leipzig, Germany
| | - K Ross
- Royal Aberdeen Children's Hospital, Scotland
| | - I Saruggia
- Centre de Reference des Maladies Héréditaires du Métabolisme du Pr. B. Chabrol CHU Timone Enfant, Marseille, France
| | - A Schlune
- Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University, Moorenstr. 5, 40225 Düsseldorf, Germany
| | | | - E Sjoqvist
- Children's Hospital, University Hospital, Lund, Sweden
| | | | - A Terry
- Alder Hey Children's Hospital NHS Foundation Trust Liverpool, UK
| | - C Timmer
- Academisch Medisch Centrum, Amsterdam, Netherlands
| | - L Tomlinson
- University Hospitals Birmingham NHS Foundation Trust, UK
| | - A Tooke
- Nottingham University Hospitals, UK
| | - K Vande Kerckhove
- Metabolic Center, University Hospitals Leuven and KU Leuven, Belgium
| | - E van Dam
- University of Groningen, University Medical Center Groningen, Netherlands
| | - T van den Hurk
- Wilhelmina Children's Hospital, University Medical Centre Utrecht, Netherlands
| | - L van der Ploeg
- Maastricht University Medical Centre + (MUMC +), Netherlands
| | | | - M van Rijn
- University of Groningen, University Medical Center Groningen, Netherlands
| | | | - A van Wegberg
- Radboud University Medical Center Nijmegen, The Netherlands
| | - C Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | - I Vitoria
- Unit of Nutrition and Metabolopathies, Hospital La Fe, Valencia, Spain
| | - D Webster
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK
| | - F J White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - L White
- Sheffield Children's Hospital, UK
| | - H Zweers
- Radboud University Medical Center Nijmegen, The Netherlands
| | - A MacDonald
- Birmingham Children's Hospital, Birmingham, UK
| |
Collapse
|
31
|
Chan H, Korobelnik J, Léger F, Durieux M, Robinet-Perrin A, Chan P, Longueville E, Paya C. Importance de la séquence de diffusion en IRM dans le diagnostic des lymphomes orbitaires. J Fr Ophtalmol 2017; 40:e37-e39. [DOI: 10.1016/j.jfo.2015.10.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 10/12/2015] [Accepted: 10/21/2015] [Indexed: 11/28/2022]
|
32
|
Chan FKL, Kyaw M, Tanigawa T, Higuchi K, Fujimoto K, Cheong PK, Lee V, Kinoshita Y, Naito Y, Watanabe T, Ching JYL, Lam K, Lo A, Chan H, Lui R, Tang RSY, Sakata Y, Tse YK, Takeuchi T, Handa O, Nebiki H, Wu JCY, Abe T, Mishiro T, Ng SC, Arakawa T. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. Gastroenterology 2017; 152:105-110.e1. [PMID: 27641510 DOI: 10.1053/j.gastro.2016.09.006] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Revised: 09/02/2016] [Accepted: 09/05/2016] [Indexed: 12/23/2022]
Abstract
BACKGROUND & AIMS It is not clear whether H2-receptor antagonists (H2RAs) reduce the risk of gastrointestinal (GI) bleeding in aspirin users at high risk. We performed a double-blind randomized trial to compare the effects of a proton pump inhibitor (PPI) vs a H2RA antagonist in preventing recurrent upper GI bleeding and ulcers in high-risk aspirin users. METHODS We studied 270 users of low-dose aspirin (≤325 mg/day) with a history of endoscopically confirmed ulcer bleeding at 8 sites in Hong Kong and Japan. After healing of ulcers, subjects with negative results from tests for Helicobacter pylori resumed aspirin (80 mg) daily and were assigned randomly to groups given a once-daily PPI (rabeprazole, 20 mg; n = 138) or H2RA (famotidine, 40 mg; n = 132) for up to 12 months. Subjects were evaluated every 2 months; endoscopy was repeated if they developed symptoms of upper GI bleeding or had a reduction in hemoglobin level greater than 2 g/dL and after 12 months of follow-up evaluation. The adequacy of upper GI protection was assessed by end points of recurrent upper GI bleeding and a composite of recurrent upper GI bleeding or recurrent endoscopic ulcers at month 12. RESULTS During the 12-month study period, upper GI bleeding recurred in 1 patient receiving rabeprazole (0.7%; 95% confidence interval [CI], 0.1%-5.1%) and in 4 patients receiving famotidine (3.1%; 95% CI, 1.2%-8.1%) (P = .16). The composite end point of recurrent bleeding or endoscopic ulcers at month 12 was reached by 9 patients receiving rabeprazole (7.9%; 95% CI, 4.2%-14.7%) and 13 patients receiving famotidine (12.4%; 95% CI, 7.4%-20.4%) (P = .26). CONCLUSIONS In a randomized controlled trial of users of low-dose aspirin at risk for recurrent GI bleeding, a slightly lower proportion of patients receiving a PPI along with aspirin developed recurrent bleeding or ulcer than of patients receiving an H2RA with the aspirin, although this difference was not statistically significant. ClincialTrials.gov no: NCT01408186.
Collapse
Affiliation(s)
- Francis K L Chan
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong.
| | - Moe Kyaw
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Tetsuya Tanigawa
- Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Kazuhide Higuchi
- Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
| | - Kazuma Fujimoto
- Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan
| | - Pui Kuan Cheong
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Vivian Lee
- School of Pharmacy, The Chinese University of Hong Kong
| | - Yoshikazu Kinoshita
- Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan
| | - Yuji Naito
- Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Toshio Watanabe
- Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Jessica Y L Ching
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Kelvin Lam
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Angeline Lo
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Heyson Chan
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Rashid Lui
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Raymond S Y Tang
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Yasuhisa Sakata
- Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan
| | - Yee Kit Tse
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Toshihisa Takeuchi
- Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
| | - Osamu Handa
- Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Hiroko Nebiki
- Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan
| | - Justin C Y Wu
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Takashi Abe
- Department of Gastroenterology, Takarazuka Municipal Hospital, Hyogo, Japan
| | - Tsuyoshi Mishiro
- Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan
| | - Siew C Ng
- Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong
| | - Tetsuo Arakawa
- Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
33
|
Farkas K, Chan H, Rutka M, Szepes Z, Nagy F, Tiszlavicz L, Nyári T, Tang W, Wong G, Tang R, Lo A, Cheung C, Wong S, Lui R, Molnár T, Ng SC. Gastroduodenal Involvement in Asymptomatic Crohn's Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe. J Crohns Colitis 2016; 10:1401-1406. [PMID: 27282400 DOI: 10.1093/ecco-jcc/jjw113] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Revised: 04/15/2016] [Accepted: 05/12/2016] [Indexed: 02/08/2023]
Abstract
BACKGROUND The incidence of Crohn's disease [CD] is increasing in Asia and Eastern Europe. Limited studies have reported on the frequency of upper gastrointestinal [GI] involvement in patients with CD in non-Western countries. This prospective study compared the rate of macroscopic and microscopic upper GI manifestations and Helicobacter pylori positivity in asymptomatic CD patients in Asia and Eastern Europe. METHODS Consecutive asymptomatic CD patients were prospectively recruited for upper GI endoscopy between 2013 and 2015 in Hong Kong and in Hungary. Endoscopy and biopsy findings were recorded and histology was performed to assess for H. pylori and microscopic signs characteristic for CD, using standardized diagnostic criteria. RESULTS One hundred and eighty CD patients [100 Hong Kong; 80 Hungary; 70.6% male; mean age, 38.5 years] and 189 controls [100 Hong Kong; 89 Hungary; 57.7% male; mean age 41 years] were included. Gastroduodenal involvement of CD was significantly higher in Hungary than in Hong Kong [16.5% vs 2.0%, p ≤ 0.001]. H. pylori positivity was significantly higher in Hungarian than Chinese CD patients [13.9% vs 4.0%, p ≤ 0.001]. Granulomas were detected in 1% in Hong Kong and 7.6% in Hungary [p ≤ 0.001]. Chinese CD subjects had a significantly lower H. pylori positivity compared with controls [6% vs. 15%; p ≤ 0.001]. CONCLUSIONS Upper GI CD was significantly higher in Eastern Europe than in Asia. The detection of granuloma in Hungary was similar to the literature data, whereas focal gastritis was lower than expected in both cohorts.
Collapse
Affiliation(s)
- Klaudia Farkas
- 1 Department of Medicine, University of Szeged, Szeged, Hungary
| | - Heyson Chan
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Mariann Rutka
- 1 Department of Medicine, University of Szeged, Szeged, Hungary
| | - Zoltán Szepes
- 1 Department of Medicine, University of Szeged, Szeged, Hungary
| | - Ferenc Nagy
- 1 Department of Medicine, University of Szeged, Szeged, Hungary
| | | | - Tibor Nyári
- Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary
| | - Whitney Tang
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Grace Wong
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Raymond Tang
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Angeline Lo
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Christina Cheung
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Sunny Wong
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Rashid Lui
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| | - Tamás Molnár
- 1 Department of Medicine, University of Szeged, Szeged, Hungary
| | - Siew C Ng
- Institute of Digestive Disease, Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong
| |
Collapse
|
34
|
Barbour A, Walpole E, Mai G, Chan H, Barnes E, Watson D, Ackland S, Wills V, Martin J, Burge M, Karapetis C, Shannon J, Nott L, Gebski V, Wilson K, Thomas J, Lampe G, Zalcberg J, Simes J, Smithers M. An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Lee I, Lunt H, Chan H, Heenan H, Berkeley J, Frampton CMA. Postprandial capillary-venous glucose gradient in Type 1 diabetes: magnitude and clinical associations in a real world setting. Diabet Med 2016; 33:998-1003. [PMID: 26536491 PMCID: PMC5064751 DOI: 10.1111/dme.13025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/28/2015] [Indexed: 12/20/2022]
Abstract
AIMS To determine the magnitude of the peripheral glucose gradient in patients with Type 1 diabetes in a real world setting and to explore its relationship with insulin dose and macronutrient intake. METHODS All patients used mealtime analogue insulin. The glucose gradient was assessed using antecubital fossa venous and finger-stick capillary samples, collected concurrently at room temperature. Baseline sampling occurred before the administration of an insulin dose and breakfast of the patient's choosing. Breakfast was consumed an average of 15 min after baseline. The macronutrient content of breakfast was documented. Sampling was repeated 1 and 2 h after baseline. RESULTS The mean (95% CI) plasma capillary-venous glucose gradient values for 43 patients were: pre-breakfast, 0.21 (0.08-0.34) mmol/l; 1 h after baseline, 0.87 (0.66-1.07) mmol/l; and 2 h after baseline, 0.52 (0.33-0.71) mmol/l. Glucose gradient and dietary carbohydrate intake (g/kg body weight) were positively correlated at both 1 h (P < 0.01) and 2 h after baseline (P < 0.01). No relationship was observed between this gradient and mealtime insulin dose, or the glucose concentration at either time point. CONCLUSIONS In patients with Type 1 diabetes, a clinically significant glucose gradient is present after the ingestion of a carbohydrate-rich meal. As postprandial capillary and venous plasma glucose concentrations are not equivalent, defining the site of sample collection is important.
Collapse
Affiliation(s)
- I Lee
- School of Medicine, University of Otago, Christchurch, New Zealand
| | - H Lunt
- Department of Medicine, University of Otago, Christchurch, New Zealand
| | - H Chan
- Canterbury District Health Board, Christchurch Diabetes Centre, Christchurch, New Zealand
| | - H Heenan
- Canterbury District Health Board, Christchurch Diabetes Centre, Christchurch, New Zealand
| | - J Berkeley
- Canterbury District Health Board, Christchurch Diabetes Centre, Christchurch, New Zealand
| | - C M A Frampton
- Department of Medicine, University of Otago, Christchurch, New Zealand
| |
Collapse
|
36
|
Chan H, Ailem Y, San S, Rougier MB, Montferme S, Dutheil C, Williamson W. Un tuberculome associé à une sclérite postérieure bilatérale révélateur d’une tuberculose ganglionnaire : à propos d’un cas. J Fr Ophtalmol 2016; 39:e151-5. [DOI: 10.1016/j.jfo.2015.03.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Accepted: 03/20/2015] [Indexed: 10/21/2022]
|
37
|
Goodsitt M, Chan H, Watcharotone K, Nan B, Christodoulou E. SU-C-206-02: Estimating Coronary Artery Plaque Composition with a Combined Dual-Energy and Single-Energy QCT Optimization Model. Med Phys 2016. [DOI: 10.1118/1.4955584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Chan H, Korobelnik JF, Pechmeja J, Morillon C, Mercier AE, Paya C. [Immature retina evolution in a premature infant]. J Fr Ophtalmol 2016; 39:227-8. [PMID: 26852386 DOI: 10.1016/j.jfo.2015.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Revised: 10/02/2015] [Accepted: 10/12/2015] [Indexed: 11/17/2022]
Affiliation(s)
- H Chan
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France.
| | - J F Korobelnik
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - J Pechmeja
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Morillon
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - A E Mercier
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - C Paya
- Service d'ophtalmologie, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
| |
Collapse
|
39
|
Kok P, Chan H, Chao C, Descallar J, Bray V, Tognela A, Yip P. 369O Timing of palliative care referral and its impact on receiving aggressive end of life care in patients with metastatic non-small cell lung cancer (NSCLC) in Southwest Sydney. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv531.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Paya C, Chan H, Pechméja J, Schweitzer C, Coste V, Andrèbe C, Korobelnik JF. [Intraoperative OCT of a Mittendorf dot with persistent hyaloid artery]. J Fr Ophtalmol 2015; 39:109-10. [PMID: 26612562 DOI: 10.1016/j.jfo.2015.04.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Revised: 04/12/2015] [Accepted: 04/27/2015] [Indexed: 11/25/2022]
Affiliation(s)
- C Paya
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France.
| | - H Chan
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| | - J Pechméja
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Schweitzer
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - V Coste
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Andrèbe
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - J-F Korobelnik
- Service d'ophtalmologie, centre François-Xavier-Michelet, CHU de Bordeaux, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Saignat, 33000 Bordeaux, France
| |
Collapse
|
41
|
Chan H, Ailem Y, San S, Williamson W. [A rare cause of optic neuropathy in sarcoidosis: Acute posterior ischemic optic neuropathy, case report]. J Fr Ophtalmol 2015; 39:e29-32. [PMID: 26584771 DOI: 10.1016/j.jfo.2015.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 01/06/2015] [Accepted: 01/07/2015] [Indexed: 10/22/2022]
Affiliation(s)
- H Chan
- Service d'ophtalmologie, centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France.
| | - Y Ailem
- Service d'ophtalmologie, centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| | - S San
- Service d'ophtalmologie, centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| | - W Williamson
- Service d'ophtalmologie, centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| |
Collapse
|
42
|
Paya C, Andrèbe C, Coste V, Chan H, Schweitzer C, Korobelnik JF. [Multimodal imaging of angle closure secondary to spherophakia in Weill-Marchesani syndrome]. J Fr Ophtalmol 2015; 38:1019-20. [PMID: 26549137 DOI: 10.1016/j.jfo.2015.04.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 04/16/2015] [Accepted: 04/17/2015] [Indexed: 11/18/2022]
Affiliation(s)
- C Paya
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France.
| | - C Andrèbe
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - V Coste
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - H Chan
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - C Schweitzer
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France
| | - J-F Korobelnik
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| |
Collapse
|
43
|
Paya C, Montfermé S, Chan H, Pechméja J, Delyfer MN, Korobelnik JF. [Persistent tunica vasculosa lentis]. J Fr Ophtalmol 2015; 38:1018. [PMID: 26545330 DOI: 10.1016/j.jfo.2015.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 03/20/2015] [Indexed: 10/22/2022]
Affiliation(s)
- C Paya
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France.
| | - S Montfermé
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| | - H Chan
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| | - J Pechméja
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| | - M-N Delyfer
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| | - J-F Korobelnik
- Service d'ophtalmologie, CHU Pellegrin, place Amélie-Raba-Léon, 33000 Bordeaux, France; Université de Bordeaux, rue Léo-Sagnat, 33000 Bordeaux, France
| |
Collapse
|
44
|
Chan C, Tam M, Chan H, Wong S. Treatment decision after IVF implantation cycle failure: Chinese female patients’ preferred role in decision making and its effects on decisional regret and psychological well-being. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Chan H, Wong S, Tam M. As both person and a professional: cultivating compassion satisfaction among healthcare practitioners specialized in assisted reproductive technologies (ART). Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.1106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Zheng S, Chan H, Epstein RJ, Joseph JE. Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma. Intern Med J 2015; 45:666-9. [DOI: 10.1111/imj.12779] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 02/13/2015] [Indexed: 11/29/2022]
Affiliation(s)
- S. Zheng
- Department of Haematology; St Vincent's Hospital; Sydney New South Wales Australia
| | - H. Chan
- Department of Oncology; St Vincent's Hospital; Sydney New South Wales Australia
| | - R. J. Epstein
- Department of Oncology; St Vincent's Hospital; Sydney New South Wales Australia
- Faculty of Medicine, St Vincent's Clinical School; University of New South Wales; Sydney New South Wales Australia
| | - J. E. Joseph
- Department of Haematology; St Vincent's Hospital; Sydney New South Wales Australia
- Faculty of Medicine, St Vincent's Clinical School; University of New South Wales; Sydney New South Wales Australia
| |
Collapse
|
47
|
Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71:326-37. [PMID: 25982025 PMCID: PMC4535279 DOI: 10.1016/j.jinf.2015.05.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 05/05/2015] [Accepted: 05/09/2015] [Indexed: 12/01/2022]
Abstract
Objectives Outer membrane vesicle (OMV) vaccines are used against outbreaks of capsular group B Neisseria meningitidis (MenB) caused by strains expressing particular PorA outer membrane proteins (OMPs). Ferric enterobactin receptor (FetA) is another variable OMP that induces type-specific bactericidal antibodies, and the combination of judiciously chosen PorA and FetA variants in vaccine formulations is a potential approach to broaden protection of such vaccines. Methods The OMV vaccine MenPF-1 was generated by genetically modifying N. meningitidis strain 44/76 to constitutively express FetA. Three doses of 25 μg or 50 μg of MenPF-1 were delivered intra-muscularly to 52 healthy adults. Results MenPF-1 was safe and well tolerated. Immunogenicity was measured by serum bactericidal assay (SBA) against wild-type and isogenic mutant strains. After 3 doses, the proportion of volunteers with SBA titres ≥1:4 (the putative protective titre) was 98% for the wild-type strain, and 77% for the strain 44/76 FetAonPorAoff compared to 51% in the strain 44/76 FetAoffPorAoff, demonstrating that vaccination with MenPF-1 simultaneously induced FetA and PorA bactericidal antibodies. Conclusion This study provides a proof-of-concept for generating bactericidal antibodies against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types can be used to formulate a vaccine for broad protection against MenB disease. MenB OMV vaccines' efficacy is strain-restricted by the variable antigen PorA. FetA is another variable antigen, but has iron-dependent expression. The combination of only a few PorA and FetA can induce broad-protection. A mutated OMV was created containing one PorA and one FetA. FetA induces bactericidal antibody response in addition to the PorA response in a Phase I trial.
Collapse
Affiliation(s)
- L Marsay
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - C Dold
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - C A Green
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - C S Rollier
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom.
| | - G Norheim
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - M Sadarangani
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - M Shanyinde
- Nuffield Department of Primary Health Care Sciences, Primary Care Clinical Trials Unit, University of Oxford, 23-38 Hythe Bridge Street, Oxford, United Kingdom
| | - C Brehony
- Department of Zoology, University of Oxford, South Parks Road, United Kingdom
| | - A J Thompson
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - H Sanders
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
| | - H Chan
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
| | - K Haworth
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| | - J P Derrick
- Michael Smith Building, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
| | - I M Feavers
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
| | - M C Maiden
- Department of Zoology, University of Oxford, South Parks Road, United Kingdom
| | - A J Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, CCVTM, Churchill Lane, Oxford OX37LE, United Kingdom
| |
Collapse
|
48
|
Aguiar A, Ahring K, Almeida MF, Assoun M, Belanger Quintana A, Bigot S, Bihet G, Blom Malmberg K, Burlina A, Bushueva T, Caris A, Chan H, Clark A, Clark S, Cochrane B, Corthouts K, Dalmau J, Dassy M, De Meyer A, Didycz B, Diels M, Dokupil K, Dubois S, Eftring K, Ekengren J, Ellerton C, Evans S, Faria A, Fischer A, Ford S, Freisinger P, Giżewska M, Gokmen-Ozel H, Gribben J, Gunden F, Heddrich-Ellerbrok M, Heiber S, Heidenborg C, Jankowski C, Janssen-Regelink R, Jones I, Jonkers C, Joerg-Streller M, Kaalund-Hansen K, Kiss E, Lammardo AM, Lang K, Lier D, Lilje R, Lowry S, Luyten K, MacDonald A, Meyer U, Moor D, Pal A, Robert M, Robertson L, Rocha JC, Rohde C, Ross K, Saruhan S, Sjöqvist E, Skeath R, Stoelen L, Ter Horst NM, Terry A, Timmer C, Tuncer N, Vande Kerckhove K, van der Ploeg L, van Rijn M, van Spronsen FJ, van Teeffelen-Heithoff A, van Wegberg A, van Wyk K, Vasconcelos C, Vitoria I, Wildgoose J, Webster D, White FJ, Zweers H. Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach. Mol Genet Metab 2015; 115:17-22. [PMID: 25862610 DOI: 10.1016/j.ymgme.2015.03.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 03/18/2015] [Accepted: 03/19/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND There appears little consensus concerning protein requirements in phenylketonuria (PKU). METHODS A questionnaire completed by 63 European and Turkish IMD centres from 18 countries collected data on prescribed total protein intake (natural/intact protein and phenylalanine-free protein substitute [PS]) by age, administration frequency and method, monitoring, and type of protein substitute. Data were analysed by European region using descriptive statistics. RESULTS The amount of total protein (from PS and natural/intact protein) varied according to the European region. Higher median amounts of total protein were prescribed in infants and children in Northern Europe (n=24 centres) (infants <1 year, >2-3g/kg/day; 1-3 years of age, >2-3 g/kg/day; 4-10 years of age, >1.5-2.5 g/kg/day) and Southern Europe (n=10 centres) (infants <1 year, 2.5 g/kg/day, 1-3 years of age, 2 g/kg/day; 4-10 years of age, 1.5-2 g/kg/day), than by Eastern Europe (n=4 centres) (infants <1 year, 2.5 g/kg/day, 1-3 years of age, >2-2.5 g/kg/day; 4-10 years of age, >1.5-2 g/kg/day) and with Western Europe (n=25 centres) giving the least (infants <1 year, >2-2.5 g/kg/day, 1-3 years of age, 1.5-2 g/kg/day; 4-10 years of age, 1-1.5 g/kg/day). Total protein prescription was similar in patients aged >10 years (1-1.5 g/kg/day) and maternal patients (1-1.5 g/kg/day). CONCLUSIONS The amounts of total protein prescribed varied between European countries and appeared to be influenced by geographical region. In PKU, all gave higher than the recommended 2007 WHO/FAO/UNU safe levels of protein intake for the general population.
Collapse
Affiliation(s)
- A Aguiar
- Hospital de Santo Espirito da Ilha Terceira, Portugal
| | - K Ahring
- Kennedy Centre, Department of Clinical Genetics, Rigshospitalet, University of Copenhagen, Glostrup, Denmark
| | - M F Almeida
- Centro de Genética Médica Doutor Jacinto de Magalhães, CHP EPE, Porto, Portugal; Multidisciplinary Unit for Biomedical Research, UMIB-FCT, Porto, Portugal
| | - M Assoun
- Service des Maladies Héréditaires du Métabolisme, Hospital Necker Enfants Malades, Paris, France
| | | | - S Bigot
- Centre Hospitalier Universitaire de Rennes, France
| | - G Bihet
- Centre Hospitalier Chrétien, Centre Pinocchio Liège, Belgium
| | | | - A Burlina
- Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padova, Italy
| | - T Bushueva
- Scientific Center of Children's Health, Moscow, Russian Federation
| | - A Caris
- Centre Wallon de Génétique Humaine, Maladies Métaboliques, CHU de Liège Sart-Tilman, Belgium
| | - H Chan
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Clark
- National Centre for Inherited Metabolic Disorders, Dublin, Ireland
| | - S Clark
- Addenbrooke's Hospital, Cambridge, UK
| | - B Cochrane
- Royal Hospital for Sick Children, Glasgow, Scotland, UK
| | - K Corthouts
- University Hospitals Leuven, Center of Metabolic Diseases, Leuven, Belgium
| | | | - M Dassy
- Cliniques Universitaires St Luc, Brussels, Belgium
| | - A De Meyer
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - B Didycz
- University Children's Hospital, Cracow, Poland
| | - M Diels
- University Hospitals Leuven, Center of Metabolic Diseases, ZOL, Genk, Belgium
| | - K Dokupil
- Dr. von Hauner Children's Hospital, Munich, Germany
| | - S Dubois
- Service des Maladies Héréditaires du Métabolisme, Hospital Necker Enfants Malades, Paris, France
| | - K Eftring
- Queen Silvia's Children Hospital, Gothenburg, Sweden
| | - J Ekengren
- Queen Silvia's Children Hospital, Gothenburg, Sweden
| | | | - S Evans
- Birmingham Children's Hospital, Birmingham, UK
| | - A Faria
- Hospital Pediatrico, Centro Hospitalar e Universitário de Coimbra, EPE, Portugal
| | - A Fischer
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - S Ford
- North Bristol NHS Trust Southmead and Frenchay, UK
| | - P Freisinger
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - M Giżewska
- Pomeranian Medical University, Szczecin, Poland
| | - H Gokmen-Ozel
- Haccettepe University Children's Hospital, Ankara, Turkey
| | - J Gribben
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - F Gunden
- Uludag University Medical Faculty, Bursa, Turkey
| | | | - S Heiber
- University Hospital, Basel, Switzerland
| | - C Heidenborg
- Karolinska University Hospital, Stockholm, Sweden
| | - C Jankowski
- University Hospitals Bristol NHS Foundation Trust, UK
| | | | - I Jones
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - C Jonkers
- Academic Medical Hospital, Amsterdam, Netherlands
| | - M Joerg-Streller
- Medical University of Innsbruck, Clinic for Pediatrics, Inherited Metabolic Disorders, Austria
| | | | - E Kiss
- Semmelweis University, Hungary
| | | | - K Lang
- Ninewells Hospital, Dundee, Scotland, UK
| | - D Lier
- Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin Reutlingen, Germany
| | - R Lilje
- Oslo University Hospital Rikshospitalet, Norway
| | - S Lowry
- Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - K Luyten
- Center of Metabolic Diseases, University Hospital, Antwerp, Belgium
| | - A MacDonald
- Birmingham Children's Hospital, Birmingham, UK.
| | - U Meyer
- Clinic of Paediatric Kidney, Liver and Metabolic Diseases Medical School Hannover, Germany
| | - D Moor
- Kinderspital Zürich, Switzerland
| | - A Pal
- Akademiska University Hospital (Children's Centre), Sweden
| | - M Robert
- Hôpital Universitaire des Enfants, Reine Fabiola, Bruxelles, Belgium
| | | | - J C Rocha
- Centro de Genética Médica Doutor Jacinto de Magalhães, CHP EPE, Porto, Portugal; Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS), Portugal
| | - C Rohde
- Hospital for Children and Adolescents, University Hospitals, University of Leipzig, Germany
| | - K Ross
- Royal Aberdeen Children's Hospital, Scotland, UK
| | - S Saruhan
- Haccettepe University Children's Hospital, Ankara, Turkey
| | - E Sjöqvist
- Children's Hospital, University Hospital Skåne, Sweden
| | - R Skeath
- Great Ormond Street Hospital for Children NHS Trust, London, UK
| | - L Stoelen
- Oslo University Hospital Rikshospitalet, Norway
| | | | - A Terry
- Alderhey Children's Hospital, Liverpool, UK
| | | | - N Tuncer
- Dokuz Eylül University Nevvar-Salih İşgören Children Hospital, Turkey
| | - K Vande Kerckhove
- University Hospitals Leuven, Center of Metabolic Diseases, Leuven, Belgium
| | | | - M van Rijn
- University of Groningen, University Medical Center, Groningen, Netherlands
| | - F J van Spronsen
- University of Groningen, University Medical Center, Groningen, Netherlands
| | | | - A van Wegberg
- Radboud University Nijmegen Medical Centre, Netherlands
| | - K van Wyk
- Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Vasconcelos
- Centro Hospitalar São João - Unidade de Doenças Metabólicas, Porto, Portugal
| | | | | | - D Webster
- University Hospitals Bristol NHS Foundation Trust, UK
| | - F J White
- Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - H Zweers
- Radboud University Nijmegen Medical Centre, Netherlands
| |
Collapse
|
49
|
Jin Z, Chan H, Ning J, Lu K, Ma D. The role of hydrogen sulfide in pathologies of the vital organs and its clinical application. J Physiol Pharmacol 2015; 66:169-179. [PMID: 25903948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 12/15/2015] [Indexed: 06/04/2023]
Abstract
Hydrogen sulfide (H(2)S) is one of the more recently recognised gaseous transmitters that have been shown to be involved in a large range of cellular functions. While H(2)S generally has pro-survival and anti-apoptotic effects, at higher concentrations, this effect is reversed and it becomes anti-proliferative and pro-apoptotic instead. H(2)S is also involved in a number of organ specific functions such as thermoregulation, modulating myocardial activity and broncho-dilation. H(2)S has organ protective effects in ischaemia, acting as a vasodilator and negative inotrope to reduce blood pressure. H(2)S generally has a protective effect in acute inflammation and oxidative stress from causes such as allergy and toxins. In chronic organ pathology, low H(2)S levels have been observed in a number of different diseases, while there is evidence that H(2)S may be beneficial in a number of chronic organ degenerations. A number of studies on human tissue and cell line conducted in the recent years shows H(2)S exerting largely similar effects in humans as those in animals. This may indicate that the pharmacological potential of H(2)S modulators could have therapeutic value in a large range of acute conditions such as ischaemia, toxin exposure as well as chronic conditions such as hypertension, lung diseases and neurodegenerative disease.
Collapse
Affiliation(s)
- Z Jin
- Section of Anesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Chelsea & Westminster Hospital, London, United Kingdom.
| | | | | | | | | |
Collapse
|
50
|
Chan H, San S, Ailem Y, Williamson W. [Atypical presentation of central retinal artery occlusion]. J Fr Ophtalmol 2015; 38:e33-6. [PMID: 25572980 DOI: 10.1016/j.jfo.2014.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Accepted: 05/23/2014] [Indexed: 11/15/2022]
Affiliation(s)
- H Chan
- Service d'ophtalmologie du centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France.
| | - S San
- Service d'ophtalmologie du centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| | - Y Ailem
- Service d'ophtalmologie du centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| | - W Williamson
- Service d'ophtalmologie du centre hospitalier de Pau, 4, boulevard Hauterive, 64000 Pau, France
| |
Collapse
|